Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes
Type 1 diabetes (T1D) is an autoimmune disease caused by the destruction of insulin-producing cells. Due to the ability of apoptotic cells clearance to induce tolerance, we previously generated liposomes rich in phophatidylserine (PS) –a feature of apoptotic cells– loaded with insulin peptides to mi...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Artificial Cells, Nanomedicine, and Biotechnology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21691401.2019.1699812 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849235709202792448 |
|---|---|
| author | Adrian Villalba Silvia Rodriguez-Fernandez Rosa-Maria Ampudia Mary Cano-Sarabia David Perna-Barrull Cesc Bertran-Cobo Clara Ehrenberg Daniel Maspoch Marta Vives-Pi |
| author_facet | Adrian Villalba Silvia Rodriguez-Fernandez Rosa-Maria Ampudia Mary Cano-Sarabia David Perna-Barrull Cesc Bertran-Cobo Clara Ehrenberg Daniel Maspoch Marta Vives-Pi |
| author_sort | Adrian Villalba |
| collection | DOAJ |
| description | Type 1 diabetes (T1D) is an autoimmune disease caused by the destruction of insulin-producing cells. Due to the ability of apoptotic cells clearance to induce tolerance, we previously generated liposomes rich in phophatidylserine (PS) –a feature of apoptotic cells– loaded with insulin peptides to mimic apoptotic beta-cells. PS-liposomes arrested autoimmunity in experimental T1D through the induction of tolerance. The aim of this study was to investigate the potential of several peptides from different T1D autoantigens encapsulated in (PS)-liposomes for T1D prevention and to assess its safety. T1D autoantigens (Insulin, C-peptide, GAD65 and IA2) were encapsulated in PS-liposomes. Liposomes were administered to the 'gold-standard' model for the study of autoimmune T1D, the Non-Obese Diabetic mouse, that spontaneously develop the disease. Safety and toxicity of liposomes were also determined. Only PS-liposomes encapsulating insulin peptides decrease T1D incidence in the Non-Obese Diabetic mouse model. Disease prevention correlates with a decrease in the severity of the autoimmune islet destruction driven by leukocytes. PS-liposomes neither showed toxic effect nor secondary complications. Among the here referred autoantigens, insulin peptides are the best candidates to be encapsulated in liposomes, like an artificial apoptotic cell, for the arrest of autoimmunity in T1D in a safe manner. |
| format | Article |
| id | doaj-art-b7b735d04d2b4ab7bf2aa7da1ed37f6b |
| institution | Kabale University |
| issn | 2169-1401 2169-141X |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Artificial Cells, Nanomedicine, and Biotechnology |
| spelling | doaj-art-b7b735d04d2b4ab7bf2aa7da1ed37f6b2025-08-20T04:02:41ZengTaylor & Francis GroupArtificial Cells, Nanomedicine, and Biotechnology2169-14012169-141X2020-01-01481778310.1080/21691401.2019.1699812Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetesAdrian Villalba0Silvia Rodriguez-Fernandez1Rosa-Maria Ampudia2Mary Cano-Sarabia3David Perna-Barrull4Cesc Bertran-Cobo5Clara Ehrenberg6Daniel Maspoch7Marta Vives-Pi8Immunology Section, Germans Trias i Pujol Research Institute, Autonomous University of Barcelona, Badalona, SpainImmunology Section, Germans Trias i Pujol Research Institute, Autonomous University of Barcelona, Badalona, SpainImmunology Section, Germans Trias i Pujol Research Institute, Autonomous University of Barcelona, Badalona, SpainCatalan Institute of Nanoscience and Nanotechnology, Bellaterra, SpainImmunology Section, Germans Trias i Pujol Research Institute, Autonomous University of Barcelona, Badalona, SpainImmunology Section, Germans Trias i Pujol Research Institute, Autonomous University of Barcelona, Badalona, SpainImmunology Section, Germans Trias i Pujol Research Institute, Autonomous University of Barcelona, Badalona, SpainCatalan Institute of Nanoscience and Nanotechnology, Bellaterra, SpainImmunology Section, Germans Trias i Pujol Research Institute, Autonomous University of Barcelona, Badalona, SpainType 1 diabetes (T1D) is an autoimmune disease caused by the destruction of insulin-producing cells. Due to the ability of apoptotic cells clearance to induce tolerance, we previously generated liposomes rich in phophatidylserine (PS) –a feature of apoptotic cells– loaded with insulin peptides to mimic apoptotic beta-cells. PS-liposomes arrested autoimmunity in experimental T1D through the induction of tolerance. The aim of this study was to investigate the potential of several peptides from different T1D autoantigens encapsulated in (PS)-liposomes for T1D prevention and to assess its safety. T1D autoantigens (Insulin, C-peptide, GAD65 and IA2) were encapsulated in PS-liposomes. Liposomes were administered to the 'gold-standard' model for the study of autoimmune T1D, the Non-Obese Diabetic mouse, that spontaneously develop the disease. Safety and toxicity of liposomes were also determined. Only PS-liposomes encapsulating insulin peptides decrease T1D incidence in the Non-Obese Diabetic mouse model. Disease prevention correlates with a decrease in the severity of the autoimmune islet destruction driven by leukocytes. PS-liposomes neither showed toxic effect nor secondary complications. Among the here referred autoantigens, insulin peptides are the best candidates to be encapsulated in liposomes, like an artificial apoptotic cell, for the arrest of autoimmunity in T1D in a safe manner.https://www.tandfonline.com/doi/10.1080/21691401.2019.1699812Nanovesiclesimmunotherapyautoimmunity |
| spellingShingle | Adrian Villalba Silvia Rodriguez-Fernandez Rosa-Maria Ampudia Mary Cano-Sarabia David Perna-Barrull Cesc Bertran-Cobo Clara Ehrenberg Daniel Maspoch Marta Vives-Pi Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes Artificial Cells, Nanomedicine, and Biotechnology Nanovesicles immunotherapy autoimmunity |
| title | Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes |
| title_full | Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes |
| title_fullStr | Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes |
| title_full_unstemmed | Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes |
| title_short | Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes |
| title_sort | preclinical evaluation of antigen specific nanotherapy based on phosphatidylserine liposomes for type 1 diabetes |
| topic | Nanovesicles immunotherapy autoimmunity |
| url | https://www.tandfonline.com/doi/10.1080/21691401.2019.1699812 |
| work_keys_str_mv | AT adrianvillalba preclinicalevaluationofantigenspecificnanotherapybasedonphosphatidylserineliposomesfortype1diabetes AT silviarodriguezfernandez preclinicalevaluationofantigenspecificnanotherapybasedonphosphatidylserineliposomesfortype1diabetes AT rosamariaampudia preclinicalevaluationofantigenspecificnanotherapybasedonphosphatidylserineliposomesfortype1diabetes AT marycanosarabia preclinicalevaluationofantigenspecificnanotherapybasedonphosphatidylserineliposomesfortype1diabetes AT davidpernabarrull preclinicalevaluationofantigenspecificnanotherapybasedonphosphatidylserineliposomesfortype1diabetes AT cescbertrancobo preclinicalevaluationofantigenspecificnanotherapybasedonphosphatidylserineliposomesfortype1diabetes AT claraehrenberg preclinicalevaluationofantigenspecificnanotherapybasedonphosphatidylserineliposomesfortype1diabetes AT danielmaspoch preclinicalevaluationofantigenspecificnanotherapybasedonphosphatidylserineliposomesfortype1diabetes AT martavivespi preclinicalevaluationofantigenspecificnanotherapybasedonphosphatidylserineliposomesfortype1diabetes |